

THE CLIMB

to find a cure for Alzheimer's

After more than 17 years of progress, we're closer than ever to stopping Alzheimer's disease before it starts. The climb is steep, but prevention trials are getting us closer — and with continued support, the summit is within reach.

What is DIAN?

The Dominantly Inherited Alzheimer Network (DIAN) follows families who carry rare genetic mutations that cause early-onset Alzheimer's, revealing the earliest changes in the brain and helping us transform inherited risk into the promise of prevention.



ACTIVE TRIALS

AMYLOID REMOVAL ART TRIAL

This continuation of DIAN-TU studies how removing amyloid protein from the brain affects disease progression and how long it can delay onset in those with inherited risk.

PRIMARY PREVENTION

Tests ultra-early therapy in young adults (18 to 25) before brain changes appear, using antibodies to prevent amyloid plaques from developing in the first place.

NEXT GENERATION NEXGEN

A prevention trial targeting two drivers of Alzheimer's: amyloid protein and tau tangles (clumps of protein that gum up brain cells), using antibodies to clear both.

TRAILBLAZING TRIALS

DIAN Obs and Trials Unit A long-term observational study showing Alzheimer's markers can appear in the brain 10 to 20 years before symptoms, helping pinpoint the earliest window for intervention. Across nearly 45 global sites, our trials unit (DIAN-TU) turns those insights into prevention studies designed to change the course of the disease.